Vivos Therapeutics (VVOS) Capital Expenditures (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Capital Expenditures for 7 consecutive years, with $416000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 46.04% year-over-year to $416000.0 in Q2 2026; TTM through Jun 2026 was $4.7 million, a 278.08% increase from a year earlier, with the FY2025 full-year figure at $5.2 million, up 812.85% from the prior year.
• Capital Expenditures was $416000.0 for Q2 2026 at Vivos Therapeutics, up from $18000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $4.4 million in Q4 2025 and troughed at -$83000.0 in Q3 2025.
• A 5-year average of $439666.7 and a median of $165000.0 in 2023 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 2551.52% in 2025, down 143.23% in 2025.
• Over 5 years, Capital Expenditures stood at $200000.0 in 2022, then declined by 17.5% to $165000.0 in 2023, then changed by 0.0% to $165000.0 in 2024, then soared by 2551.52% to $4.4 million in 2025, then plunged by 90.49% to $416000.0 in 2026.
• The last three Capital Expenditures figures came in at $416000.0 (Q2 2026), $18000.0 (Q1 2026), and $4.4 million (Q4 2025), per Business Quant data.